Core Viewpoint - The Court has granted preliminary approval for a $65 million settlement in an antitrust class action against Actelion Pharmaceuticals, now part of Johnson & Johnson, for allegedly preventing generic drug manufacturers from developing a cheaper version of its drug Tracleer [1] Group 1: Lawsuit Details - The lawsuit was initiated by the Government Employees Health Association (GEHA), which claimed that Actelion obstructed generic manufacturers from obtaining necessary samples of Tracleer, thereby hindering the market entry of generic alternatives [2] - GEHA alleged that Actelion not only refused to sell samples but also contractually prevented competitors from acquiring samples from pharmacies, effectively blocking all avenues for generic manufacturers [2] - The alleged actions resulted in no generic product being available for nearly four years after the Tracleer patent expired, leading to over $100 million in overpayments by GEHA and other Third-Party Payors for the drug [2] Group 2: Settlement and Impact - The settlement amount of $65 million represents nearly 50% of the conservative single damages estimate, providing significant relief to the class of entities that purchased Tracleer [3] - If finalized, the settlement will resolve over seven years of litigation and deliver compensation to those affected by the alleged antitrust practices [3] Group 3: Drug Information - Tracleer, the brand name for bosentan, is used to treat pulmonary artery hypertension (PAH), a chronic and potentially fatal condition affecting 10,000 to 20,000 people in the U.S., primarily women [4] - At the time of the alleged antitrust scheme, Actelion charged $75,000 per patient annually for Tracleer [4] Group 4: Legal Proceedings - The lawsuit was originally filed in 2018 but was dismissed in 2019 due to statute of limitations issues; however, the Fourth Circuit revived the case in 2021, allowing it to proceed [5] - The district court granted class certification for GEHA in September 2024, denying Actelion's motion for summary judgment, which set the stage for the trial [5]

Core Insights - Johnson & Johnson (NYSE: JNJ) is involved in a $65 million antitrust class action settlement related to its pulmonary hypertension drug Tracleer, which allegedly delayed competition for a generic version of the medication [2] - The company operates through two main segments: Innovative Medicine, focusing on therapeutic areas such as oncology and immunology, and MedTech, which includes a wide range of medical devices [3] Group 1 - Johnson & Johnson units have agreed to pay $65 million to settle claims from health plans alleging overcharging for Tracleer [2] - The lawsuit claimed that Johnson & Johnson obstructed competitor access to Tracleer samples, hindering the market entry of generic alternatives [2] - Actelion Pharmaceuticals, which developed Tracleer and was acquired by Johnson & Johnson in 2017, reportedly made billions in profits from the drug [2] Group 2 - The Innovative Medicine segment of Johnson & Johnson focuses on various therapeutic areas, including oncology, infectious diseases, and cardiovascular diseases [3] - The MedTech segment encompasses a diverse range of medical devices used in fields such as cardiovascular intervention and orthopedics [3]

Core Viewpoint - Johnson & Johnson units have agreed to pay $65 million to settle an antitrust class action lawsuit regarding the pulmonary hypertension drug Tracleer, which alleged overcharging and delayed competition for a generic version of the drug [1]. Group 1: Settlement Details - The preliminary settlement was filed in federal court in Maryland and requires judicial approval [1]. - The settlement covers Tracleer purchases in 31 states, the District of Columbia, and Puerto Rico from December 2015 to September 2024 [1]. - Plaintiffs plan to seek approximately 33% of the settlement fund for legal fees, amounting to about $21 million [1]. Group 2: Allegations and Background - The lawsuit, initiated in 2018, claimed that the drugmakers impeded competitor access to Tracleer samples, effectively blocking the market entry of a competing generic product [1]. - Actelion Pharmaceuticals, which made billions from Tracleer sales, was acquired by Johnson & Johnson in 2017 [1]. - The plaintiffs include the Government Employees Health Association and other entities that reimbursed members for Tracleer usage [1].

Core Viewpoint - The company announced that its wholly-owned subsidiary, Huaren Shuanghe Limin Pharmaceutical (Jinan) Co., Ltd., has received a drug registration certificate for Bosentan dispersible tablets from the National Medical Products Administration (NMPA) [1][2]. Group 1: Drug Registration and Development - The drug Bosentan dispersible tablets are indicated for pulmonary arterial hypertension (PAH) in pediatric patients aged 3 years and older, as well as for adult patients classified as WHO functional class II to IV [1][2]. - The development of this generic drug began in 2022, with the application for marketing authorization submitted on June 14, 2024, and approval granted on September 23, 2025 [2]. Group 2: Market Situation - Bosentan dispersible tablets were developed by Actelion Pharmaceuticals Ltd and were approved for sale in the EU in 2009 under the brand name "Tracleer." The drug was imported into China in September 2019 under the brand name "Quankeli" [3]. - In 2024, the global sales of Bosentan dispersible tablets reached approximately $35.9 million, with "Tracleer" accounting for about $31.3 million of that total [3]. - In the Chinese market, the total sales of Bosentan dispersible tablets were approximately 2.126 million yuan in 2024, with Johnson & Johnson holding a 100% market share [3]. Group 3: Impact on the Company - The acquisition of the drug registration certificate is expected to enhance the company's product line and market competitiveness, while also providing valuable experience for future product development [4].